A Study of Metabolic Agents Following Brain Radiation

Mayo Clinic5 enrolled

Overview

This study is being done to determine if CEST magnetic resonance imaging (MRI) and FDG PET are feasible techniques to detect metabolic differences between tumor and brain in patients with a brain tumor.

Study Type

OBSERVATIONAL

Enrollment

Conditions

CNS Malignancy

Interventions

FDG Positron Emission TomographyDIAGNOSTIC_TEST

Imaging using an FDG radioactive tracer to look at the head.

Chemical Exchange Saturation Transfer Magnetic Resonance ImagingDIAGNOSTIC_TEST

A noninvasive diagnostic test for measuring biochemical changes in the brain, especially the presence of tumors.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Radiographic evidence or histopathologic confirmation of CNS malignancy, with or without prior resection. * Provide written informed consent for the current study. * Willing to undergo at least one MRI (and possibly more at PI discretion) with proton and/or phosphorus magnetic resonance spectroscopy analysis. Exclusion Criteria: * Vulnerable populations: pregnant or nursing women (Arm B exempt), prisoners, mentally handicapped. * Cardiac pacemaker or artificial heart valve * Metal plate, pin, or other metallic implant * Intrauterine device, such as Copper-7 IUD * Insulin or other drug pump * Non-titanium aneurysm clips * Previous gunshot wound * Cochlear implant or other hearing device * Employment history as a metalworker (had metal in eye) * Permanent (tattoo) eye-liner * For FDG-PET specifically: Fasting blood sugar level greater than 200mg/dl

Locations (1)

Mayo Clinic

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

Number of subjects in whom glutamate metabolite is detected and measurable.

Number of subjects in whom glutamate metabolite is detected and measurable via CEST MRI in tumor, brain, and/or the ventricular space.

Time frame: Baseline

Number of subjects in whom n-acetylaspartate (NAA) metabolite is detected and measurable.

Number of subjects in whom n-acetylaspartate (NAA) metabolite is detected and measurable via CEST MRI in tumor, brain, and/or the ventricular space.

Time frame: Baseline

Secondary Outcomes

Time required to perform the CEST MRI study and measure metabolites of interest

Total time expressed in minutes required to perform the CEST MRI study and measure metabolites of interest.

Time frame: Duration of CEST MRI scan, approximately one to two hours.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.